DiaPep277® Preserves Endogenous Insulin Production by Immunomodulation in Type 1 Diabetes
- 1 October 2006
- journal article
- clinical trial
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1079 (1) , 340-344
- https://doi.org/10.1196/annals.1375.052
Abstract
DiaPep277 is an immunomodulatory peptide that arrests beta cell destruction in mouse models of type 1 diabetes mellitus (T1DM). This article extends an original pilot observation to two studies of 61 patients (age > 16 years), diagnosed with T1DM within 6 months, and with measurable beta cell function. Patients were treated with placebo (n = 27) or 1.0 mg DiaPep277 (n = 34). After 13 months, 1.0 mg Dia Pep277 treatment significantly (P = 0.02) preserved beta cell function as compared to the control with a trend for reduced HbA1c. This was achieved without an increase in insulin dose in the DiaPep277 group and with excellent safety. DiaPep277-treated patients also had fewer Th1 DiaPep277-specific T cells.Keywords
This publication has 6 references indexed in Scilit:
- T cells respond to heat shock protein 60 via TLR2: activation of adhesion and inhibition of chemokine receptorsThe FASEB Journal, 2003
- Human Heat Shock Protein 60 Induces Maturation of Dendritic Cells Versus a Th1-Promoting PhenotypeThe Journal of Immunology, 2003
- β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trialThe Lancet, 2001
- Treatment of Autoimmune Diabetes and Insulitis in NOD Mice With Heat Shock Protein 60 Peptide p277Diabetes, 1995
- Treatment of autoimmune diabetes and insulitis in NOD mice with heat shock protein 60 peptide p277Diabetes, 1995
- Peptide therapy for diabetes in NOD miceThe Lancet, 1994